ACTG 329: NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS

ACTG 329： 癸酸诺龙治疗与 HIV 相关的女性体重减轻

• 批准号: 6264517
• 负责人: Kathleen Mulligan
• 金额: $ 0.06万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264517
• 关键词: AIDS therapy; HIV infections; androgen analog; bioenergetics; body weight; cachexia; clinical research; clinical trial phase I; drug screening /evaluation; female; functional ability; human subject; human therapy evaluation; quality of life; sex hormones; weight loss

This is a multicenter study designed to evaluate the safety and efficacy of nandrolone decanoate in women with HIV-associated weight loss. Secondary objectives include evaluation of the effects of nandrolone on body weight, sex hormones, quality of life, and activity level; and of the role, if any, of energy intake and sex hormones on the magnitude of response to therapy.

这是一项多中心研究，旨在评估正庚酸诺孕酮治疗HIV相关减肥女性的安全性和有效性。次要目标包括评估南多隆对体重、性激素、生活质量和活动水平的影响；以及能量摄入量和性激素对治疗反应程度的作用(如果有的话)。